CYFRA21-1 might be a predictive marker in advanced NSCLC
More research called for study findings confirmation
- Date : 22 Mar 2012
- Topic : Lung and other thoracic tumours
Researchers found that CYFRA and change in levels of CYFRA were reliable markers for response to chemotherapy for non-small cell lung cancer (NSCLC) in a study of 88 patients. Research presented in the April 2012 issue of the International Association for the Study of Lung Cancer's (IASLC) Journal of Thoracic Oncology shows that this marker can be used to determine whether or not a patient should continue a particular chemotherapy regimen.
Measuring CYFRA concentrations
As part of a study performed by the Cancer and Leukaemia Group B in advanced NSCLC, serum CYFRA levels were measured at baseline and after the first cycle of treatment. The study results show that higher baseline CYFRA concentrations portend worse overall and failure free survival.
This trial confirmed the significance of the cut point of a 27% reduction in log CYFRA after chemotherapy is of value in determining benefit from the treatment.
Researchers warn that further studies are needed, but if confirmed, this could provide a simple and inexpensive approach to assessment of response to treatment. The lead author of the study is Dr. Martin Edelman.
Thank you for rating!
You have already rated this page, you can only rate it once!